Search results

Order by most recent / most popular / relevance

Results: 1-10 of 324

Supreme Court declines to hear Eli Lilly’s “promise of the patent” appeal

Bereskin & Parr LLP
-
Canada
-
May 16 2013

The Supreme Court of Canada denied leave to appeal today from the Federal Court of Appeal ("FCA") decision in Eli Lilly Canada Inc v Novopharm Ltd

What goes upmust come down: Viagra patent invalidated by Canadian Supreme Court

Drinker Biddle & Reath LLP
-
Canada
-
May 13 2013

Pfizer and Teva have been fighting a legal battle over Pfizer's patent for Viagra in Canada. The first shot was fired when Novopharm Limited, now

Supreme Court of Canada denies leave to appeal in PM(NOC) judicial comity case

Bereskin & Parr LLP
-
Canada
-
May 9 2013

The Supreme Court of Canada denied leave to appeal today from the Federal Court of Appeal ("FCA") decision in Allergan Inc. et al ats. Apotex Inc

Dispelling the Myriad gene patent harmonization myth

Foley & Lardner LLP
-
Australia, Canada, European Union, France, Germany, Japan, USA
-
April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Authorized generics in the hypothetical world of generic damages

Gowling Lafleur Henderson LLP
-
Canada
-
April 22 2013

Canada, as in other jurisdictions, links drug marketing approval with patent rights. Innovative drug manufacturers may list relevant patents against

An end to generic claims for innovator profits?

Gowling Lafleur Henderson LLP
-
Canada
-
April 22 2013

Until January 2013, the law of generic claims under section 8 of the Patent Medicines (Notice of Compliance) Regulations (the "NOC Regulations"

USTR slams Canada over the treatment of pharmaceutical patents

Norton Rose Canada LLP
-
Canada
-
May 6 2013

On May 1, 2013, the United States Trade Representative (“USTR”) released its annual IP report for 2013. Canada has been placed on the “Watch List"

Generic ordered to pay $1.7 million in accounting of profits

Gowling Lafleur Henderson LLP
-
Canada
-
April 22 2013

On March 12, 2013, the Federal Court released its decision in Apotex Inc. v. H. Lundbeck AS, 2013 FC 192. The Court dismissed Apotex's action to

Teva Canada Innovation v. Attorney General of Canada

Borden Ladner Gervais LLP
-
Canada
-
May 8 2013

The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an

Mylan Pharmaceuticals ULC v. Pfizer Canada Inc., 2012 FCA 103 - Aricept (donepezil), appeal of NOC case

Gowling Lafleur Henderson LLP
-
Canada
-
April 3 2012

The Court of Appeal upheld on Order prohibiting the Minister of Health from issuing a NOC to Mylan for donepezil, a drug for the treatment of Alzheimer's type dementia, until expiry of Pfizer’s ‘808 Patent

next >

Search results

Supreme Court declines to hear Eli Lilly’s “promise of the patent” appeal

What goes upmust come down: Viagra patent invalidated by Canadian Supreme Court

Supreme Court of Canada denies leave to appeal in PM(NOC) judicial comity case

Dispelling the Myriad gene patent harmonization myth

Authorized generics in the hypothetical world of generic damages

An end to generic claims for innovator profits?

USTR slams Canada over the treatment of pharmaceutical patents

Generic ordered to pay $1.7 million in accounting of profits

Teva Canada Innovation v. Attorney General of Canada

Mylan Pharmaceuticals ULC v. Pfizer Canada Inc., 2012 FCA 103 - Aricept (donepezil), appeal of NOC case

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea